Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
10,315,270
-
Share change
-
-197,146
-
Total reported value
-
$43,896,766
-
Put/Call ratio
-
57%
-
Price per share
-
$4.24
-
Number of holders
-
84
-
Value change
-
-$59,992
-
Number of buys
-
36
-
Number of sells
-
41
Institutional Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q3 2025
As of 30 Sep 2025,
GALECTIN THERAPEUTICS INC - COM NEW (GALT) was held by
84 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
10,315,270 shares.
The largest 10 holders included
VANGUARD GROUP INC, OSAIC HOLDINGS, INC., BlackRock, Inc., GEODE CAPITAL MANAGEMENT, LLC, MARSHALL WACE, LLP, Wealthspire Advisors, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, LPL Financial LLC, Geneos Wealth Management Inc., and COMMONWEALTH EQUITY SERVICES, LLC.
This page lists
84
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.